Neurogene INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
NGNE
Neurogene INCNeurogene Inc. reported a widened net loss for 2025 while making significant clinical and regulatory progress with its lead gene therapy candidate, NGN-401, for Rett syndrome.
NASDAQ
NGNE
Neurogene INCNeurogene Inc.'s 2024 10-K filing reveals a year of significant clinical advancements and financial activities, including progress in Rett syndrome treatment and a private placement closing.
NASDAQ
NGNE
Neurogene INCNeurogene Inc.'s 10-K filing details its capital structure, ongoing clinical trials for NGN-401 and NGN-101, and its proprietary EXACT technology.